JVCI recommendations on use of Dengue vaccine in the UK were published on 21/03/24.
Dengue vaccine (Qdenga) is most effective in persons who have experienced previous Dengue infection.
The JCVI has recommended that the following groups could be offered the Qdenga® vaccine:
Individuals aged 4 years of age and older with confirmed dengue infection in the past who are planning to travel to areas where there is a risk of dengue infection, or areas with an ongoing outbreak of dengue, or are exposed to dengue virus through their work, for example, laboratory staff working with the virus
Guidance, and a new dengue chapter for the UKHSA ‘Immunisation against infectious disease’, also known as the ‘Green Book’ is currently being developed and should be available in the coming weeks.
Qdenga® is contraindicated in:
- Pregnant women
- Breastfeeding women
- Immunocompromised individuals
- Those with hypersensitivity to any component of the vaccine
- Children under 4 years of age
The JCVI do not consider the evidence on efficacy against strains of dengue 3 and dengue 4 strong enough to recommend this vaccine to individuals who have not previously been infected with dengue fever.
Travellers in these groups who are contraindicated, or who are not recommended to have dengue vaccine should be informed of the risks of dengue and instructed on mosquito avoidance measures.
